Immune Checkpoint Inhibitor plus Anti-VEGF/TKI Combined with Transarterial Chemoembolization in Locally Advanced Nonmetastatic Hepatocellular Carcinoma: Real-World Treatment Strategy Based on Phase 3 Clinical Trial Results.

Liver Cancer · 2025 · PMC12043110 · PMID 40308722

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

The death events were 15.2% in the LEN plus PEM plus TACE group and 5.2% in the TACE alone group, again with a slight trend toward more death events in the combination therapy group at this final analysis for PFS.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.